Head-to-head evidence
HM15275 vs retatrutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
HM15275
Developed by Hanmi Pharmaceutical
NCT06481098 · Phase 1 · completed
The trial randomized participants against a matched placebo with full blinding, but its primary measures were safety and tolerability rather than a body-weight or metabolic efficacy outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: January 2027 · NCT07205900 (registry estimate)
retatrutide
Developed by Eli Lilly
NCT04881760 · Phase 2 · completed
The trial randomized 338 participants to double-blinded weekly LY3437943 or matched placebo. Its primary clinical endpoint, mean percent change in body weight at Week 24, was significantly favorable for every LY3437943 dose compared with placebo (all p<0.001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT06662383 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HM15275's landscape · retatrutide's landscape